Logo

American Heart Association

  32
  0


Final ID: MP1421

PREVENT in the 75-and-older population and additional prognostic value of coronary artery calcium: the Atherosclerosis Risk in Communities (ARIC) study

Abstract Body (Do not enter title and authors here): Background: The American Heart Association recently released the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equation for estimating cardiovascular disease (CVD) risk in primary prevention adults aged 30-79. However, its performance in older adults aged 80 years and older is uncertain. Also, the utility of coronary artery calcium (CAC) for CVD prediction improvement beyond PREVENT is unknown.
Methods: We studied 1,912 ARIC older adult participants (mean age 80 [SD 4] years) with CAC data but without a history of coronary heart disease (CHD), stroke, and heart failure (HF) at Visit 7 (2018-2019). We first assessed c-statistics and calibration indices of the PREVENT in our older adult population. Then, we compared the predictability between PREVENT and CAC, with total CVD (atherosclerotic CVD [ASCVD, including CHD and stroke] and HF), and all-cause mortality as outcomes of interest, using Cox regression models.
Results: Over a median follow-up of 3.7 (IQI 2.6-4.3) years, there were 144 CVD events (81 ASCVD and 75 HF) and 210 deaths. PREVENT demonstrated good calibration (calibration slope 0.74 for total CVD) and discrimination (c-statistic 0.621), and the results were similar in participants aged 80+ vs. those aged 75-79 years. CAC significantly improved prediction of total CVD (0.078 [95% CI 0.034, 0.122]), ASCVD (0.083 [0.026, 0.140]), and HF (0.069 [0.016, 0.123]) beyond PREVENT, but this was not the case for all-cause mortality (left panel of Figure). In contrast, PREVENT improved only the prediction of all-cause mortality beyond CAC (right panel of Figure). The results were largely similar between the age of 80+ vs. 75-79.
Conclusions: PREVENT overall performed well even in older adults aged 80+ years. CAC further improved CVD risk prediction beyond and above PREVENT in the-75-and-older adults. Our findings suggest broad usefulness of PREVENT and further support the value of CAC for assessment of primary CVD risk in very older adults.
  • Mok, Yejin  ( Johns Hopkins University , Baltimore , Maryland , United States )
  • Honda, Yasuyuki  ( Johns Hopkins Bloomberg School , Baltimore , Maryland , United States )
  • Wang, Frances  ( Johns Hopkins Bloomberg School , Baltimore , Maryland , United States )
  • Howard, Candace  ( University of Mississippi Medical C , Jackson , Mississippi , United States )
  • Folsom, Aaron  ( UNIVERSITY OF MINNESOTA , Minneapolis , Minnesota , United States )
  • Coresh, Josef  ( NYU Grossman School of Medicine , New York , New York , United States )
  • Budoff, Matthew  ( LUNDQUIST INSTITUTE , Torrance , California , United States )
  • Blaha, Michael  ( JOHNS HOPKINS HOSPITAL , Baltimore , Maryland , United States )
  • Matsushita, Kunihiro  ( JOHNS HOPKINS UNIVERSITY , Baltimore , Maryland , United States )
  • Author Disclosures:
    Yejin Mok: DO NOT have relevant financial relationships | Yasuyuki Honda: No Answer | Frances Wang: No Answer | Candace Howard: DO NOT have relevant financial relationships | Aaron Folsom: DO NOT have relevant financial relationships | Josef Coresh: DO have relevant financial relationships ; Advisor:Soma Logic:Active (exists now) ; Individual Stocks/Stock Options:Healty.io:Active (exists now) | Matthew Budoff: DO have relevant financial relationships ; Researcher:Lilly:Active (exists now) ; Speaker:Boehringer-Ingleheim:Active (exists now) ; Speaker:Lilly:Active (exists now) ; Speaker:Novo Nordisk:Active (exists now) ; Researcher:Novartis:Active (exists now) ; Researcher:Amgen:Active (exists now) | Michael Blaha: DO have relevant financial relationships ; Research Funding (PI or named investigator):Novo Nordisk:Active (exists now) ; Consultant:Eli Lilly:Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Astra Zeneca:Past (completed) ; Consultant:New Amsterdam:Active (exists now) ; Consultant:Agepha:Active (exists now) ; Consultant:Merck:Active (exists now) ; Consultant:Idorsia:Past (completed) ; Consultant:Genentech:Past (completed) ; Consultant:Bayer:Active (exists now) ; Consultant:Novo Nordisk:Active (exists now) ; Research Funding (PI or named investigator):Bayer:Active (exists now) | Kunihiro Matsushita: DO have relevant financial relationships ; Consultant:RhythmX AI:Past (completed) ; Other (please indicate in the box next to the company name):Fukuda Denshi:Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:
More abstracts on this topic:
Cigar smoking and better quality of life positively impact cigarette smoking cessation in adults: Findings from the Population Assessment of Tobacco and Health Study, a national longitudinal cohort study

Majeed Ban, Kaplan Bekir, Ketchem Justin, Walsh David

Association of Delayed Diagnosis of Transthyretin Cardiomyopathy with Heart Failure Hospitalizations and Mortality

Spencer-bonilla Gabriela, Huang Joanna, Witteles Ronald, Heidenreich Paul, Sandhu Alexander, Alexander Kevin, Fan Jun, Cheng Paul, Din Natasha, Rodriguez Fatima, Varshney Anubodh, Davies Marie, Venditto John, Papas Mia

You have to be authorized to contact abstract author. Please, Login
Not Available